JelloX Biotech Inc.

🚀 Pioneering the Future of Colon Cancer Detection: JelloX & Taipei Medical University Hospital Partnership 🌟 We are excited to announce that JelloX Biotech, a leader in 3D smart pathology technology, has successfully completed clinical validation for its 3D pathology detection of colon polyps, in collaboration with Taipei Medical University Hospital (TMUH). This breakthrough technology marks a new era in the accuracy and precision of colon cancer detection, offering unprecedented possibilities for cancer prevention and treatment. 💡 Why is this so important? Colorectal cancer is one of the most common cancers worldwide, often arising from adenomatous polyps in the intestinal wall. These polyps are typically benign at first, but over time, they can mutate and evolve into cancer. Early detection significantly increases the likelihood of a cure, but because early symptoms are often subtle, many patients are diagnosed at later stages. 🔬 JelloX's 3D pathology technology provides a game-changing solution. Traditional 2D pathology methods have limitations, capturing only minute tissue samples that may miss critical details. For example, 2D pathology may only examine a 5-6 micrometer thick slice of a polyp, potentially leaving crucial information unexamined. With JelloX's advanced 3D technology, pathologists gain detailed, comprehensive tissue imagery that allows for a more thorough examination of the entire polyp, dramatically enhancing the accuracy of detection and improving patient outcomes. 🌍 This partnership with TMUH is just the beginning. By improving early detection and diagnostic accuracy, we are opening the door to a future where colon cancer can be prevented before it starts. We look forward to continuing our mission to revolutionize pathology and bring new hope for cancer prevention and treatment. More details: https://lnkd.in/gTydSG9B #Innovation #CancerPrevention #3DPathology #Healthcare #MedicalTechnology #ColorectalCancer #JelloX #TMUH #MedicalInnovation #Pathology #HealthTech

Exciting news in the fight against cancer! 🎉 JelloX Biotech Inc. Biotech and Mayo Clinic are joining forces to revolutionize cancer diagnosis through AI-enhanced 3D pathology imaging. 🔬🧠 This innovative collaboration aims to overcome limitations of traditional 2D imaging, providing a more comprehensive and accurate view of tumors. 🩻➡️🌐 By combining 3D imaging with #AI analysis, this technology promises to enhance diagnostic accuracy, improve treatment selection, and ultimately lead to better patient outcomes. 🙏 https://lnkd.in/eX4vjHDG

We are thrilled to announce that our CEO, Dr. Yen-Yin Lin, has been invited to speak at the 22nd Annual Meeting of the Japanese Society of Digital Pathology! This prestigious event brings together thought leaders and innovators in the field of digital pathology, and we are honored to take part in the ongoing revolutionary advancements in digital pathology. Stay tuned for updates and insights from Dr. Lin’s session as we continue to push the boundaries of digital pathology together! We look forward to all the engaging and insightful sessions and meet everyone that are attending! #DigitalPathology #HealthcareInnovation #3DPathology #MedicalTechnology

Understand the fact from multiple point of view

It is our honor to talk about the future of digital pathology in Life Science Success Podcast at BIO International Convention! We look forward to working hardly in the field of 3D digital pathology and precision medicine. #LifeScienceSuccess #biotech #innovation

It’s our great pleasure to have interview with Don at IS Bio 2024. JelloX Biotech Inc. #digital pathology #3D pathology game changer

JelloX is part of the Mayo Clinic and Arizona State University Alliance for Health Care. The accelerator in Mayo Clinic is amazing. We not only did research but also thought about how to commercialize the technology. We believe the collaboration among JelloX, Mayo Clinic and ASU can solve the most cancer patients in the world. Business + Technology = The Future of JelloX! https://lnkd.in/gQza7aM5 #Digital #pathology #accelerator #startup #healthcare #biotech #ai

2024 Taiwan Smart Health Gala! Thank you Louis Chen, M.S. for introducing JelloX Biotech Inc. to all the audiences. June 6th is the last day of BIO US 2024 and JelloX will be their booth too. Come to visit us at booth #1917!

Come and visit us at Bio Convention 2024 ! https://lnkd.in/g7VXza4h Learn how JelloX's 3D pathology can be a game changer! Steven Lester MD Rahul Pannala ASU OASIS Yen-Yin Lin Louis Chen, M.S. Servina Liu

What a wonderful speech! It is our great honor to be invited as a speaker in the session of Empowering Real World Patient-Centric Digital Health in Asia with Digital Apps at BIO US 2024. Our CEO, Yen-Yin Lin, talked about the opportunity of 3D imaging from real world data observation. We believe JelloX would be the solution of next generation pathology, empowered by digital apps into clinic applications. Also, sincerely thank you for our moderator and other speakers Peter Kurz Amy Hsiao Ed Deng Steven Lester MD. Furthermore, we would like to say thank you to all of you who shared the feedback with us after the speech. JelloX will be in the booth #1917 from Tuesday to Thursday this week in San Diego Convention Center Corporation. Come to stop by our booth if you want to know more about the next generation of digital pathology! #innovation #digitalpathology #biotech #leadership #ai #simulation #diagnosis #clinic #digitalapps